| Autor: |
Rochigneux P; Department of Medical Oncology, Paoli-Calmettes Institute, 232 Boulevard Sainte Marguerite, 13009 Marseille, France.; Team Immunity and Cancer, Centre de Recherche en Cancérologie de Marseille (CRCM), INSERM U1068, CNRS UMR 7258, Paoli-Calmettes Institute, Aix-Marseille University, 13009 Marseille, France., Chanez B; Department of Medical Oncology, Paoli-Calmettes Institute, 232 Boulevard Sainte Marguerite, 13009 Marseille, France., De Rauglaudre B; Department of Medical Oncology, Paoli-Calmettes Institute, 232 Boulevard Sainte Marguerite, 13009 Marseille, France., Mitry E; Department of Medical Oncology, Paoli-Calmettes Institute, 232 Boulevard Sainte Marguerite, 13009 Marseille, France., Chabannon C; Centre for Clinical Investigation in Biotherapy, Paoli-Calmettes Institute, Aix-Marseille University, INSERM CBT 1409, 13009 Marseille, France., Gilabert M; Department of Medical Oncology, Paoli-Calmettes Institute, 232 Boulevard Sainte Marguerite, 13009 Marseille, France. |
| Abstrakt: |
The mortality of hepatocellular carcinoma (HCC) is quickly increasing worldwide. In unresectable HCC, the cornerstone of systemic treatments is switching from tyrosine kinase inhibitors to immune checkpoints inhibitors (ICI). Next to ICI, adoptive cell transfer represents another promising field of immunotherapy. Targeting tumor associated antigens such as alpha-fetoprotein (AFP), glypican-3 (GPC3), or New York esophageal squamous cell carcinoma-1 (NY-ESO-1), T cell receptor (TCR) engineered T cells and chimeric antigen receptors (CAR) engineered T cells are emerging as potentially effective therapies, with objective responses reported in early phase trials. In this review, we address the biological rationale of TCR/CAR engineered T cells in advanced HCC, their mechanisms of action, and results from recent clinical trials. |
